Today’s market setup is a little less comfortable for the AI trade. Chip stocks are under pressure as investors question valuations, Hormuz risk is back on the energy board, and Vertex’s $10 billion Crinetics deal shows biotech M&A still has a pulse.

After analyzing thousands of companies, our analysts pinpointed the 5 Stocks Set to Double based on accelerating performance, improving fundamentals, and strong technical signals.

This newly released report explains why these five could be positioned for major moves in the year ahead.

While results aren’t guaranteed, previous reports uncovered gains as high as +175%, +498%, and +673%.

Access the free report before midnight.

See the 5 Stocks Set to Double.

*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.

Futures are mixed after the Dow’s record-setting push above 53,000, but chip weakness is back in focus overseas. Nasdaq names are feeling the pressure as Asian and European semiconductor stocks sell off, even after Samsung’s profit surge showed AI demand is still doing real work. Traders are also watching SpaceX’s Nasdaq-100 entry and this morning’s trade deficit data.

Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.

Email’s great. Texts are faster.

👉 Click here to get our pre-market report to your cell for free!

You’ll be first in line when the market starts moving.

Earnings (Premarket):
• No major premarket earnings scheduled

Earnings (Aftermarket):
• Penguin Solutions, Inc. [PENG]
• Enerpac Tool Group Corp. [EPAC]
• Kura Sushi USA, Inc. [KRUS]
• Saratoga Investment Corp [SAR]

Economic Reports:
• No major economic reports scheduled

You’re watching two premium growth charts from the outside, where AI infrastructure and cancer diagnostics still give investors plenty of reasons to stay bullish. But Elite Trade Club Insider readers are seeing the part the crowd usually notices late: insiders are turning massive rallies into cash while the stories still sound strongest.

Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.

A subscription gets you:

$25/mo or $250/yr. 30-day money back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.

AI Jitters Hit Asia After Samsung’s Blowout Forecast
Asian stocks tumbled after Samsung’s massive profit forecast still failed to calm AI valuation fears, with South Korean chip names leading the pullback. The market read is that investors still believe in the AI cycle, but they are no longer willing to pay any price for exposure.

Wall Street Looks for Fed Clues as Tech Wobbles
Investors are watching Fed minutes and early earnings signals after a strong quarter left the S&P 500 more dependent on profit confirmation. That puts the next few sessions in a cleaner test: rates need to stay manageable, and earnings need to prove the rally is more than AI multiple expansion.

Hedge Funds Keep Cutting Chip Exposure
Hedge funds sold tech hardware and semiconductor stocks for a fourth straight week, according to a Goldman Sachs client note cited by Reuters. That does not mean the AI trade is dead, but it does show institutional money taking profits before earnings decide which chip names deserve their premiums.

Ford Locks In Memory Supply With Micron
Micron and Ford signed a long-term semiconductor supply agreement for memory and storage platforms used in next-generation vehicles. The bigger takeaway is that AI data centers are tightening memory markets so much that automakers are moving early to protect their own chip supply.

State AGs Push Back on New Forced-Labor Tariffs
A group of Democratic attorneys general opposed the Trump administration’s proposed tariffs tied to forced-labor enforcement concerns. For markets, the issue is less about one tariff line and more about another layer of trade uncertainty hitting companies already managing supply-chain reshoring, China exposure, and margin pressure.

Supply-Chain Pressure Finally Eases
The New York Fed said global supply-chain pressures eased in June, helped by improving shipping conditions after Middle East disruptions. That is a useful inflation relief signal, but the index remains elevated enough to keep logistics, energy, and trade policy on the market’s risk list.

Only a tiny percentage of stocks meet the criteria for this report.

Analysts have released a new edition highlighting seven names selected using multiple indicators.

Recent picks have delivered notable short-term gains, though results can vary.

The latest report is now available for a limited time.

Download the free report today.

*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.

*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.

Hormuz Risk Comes Back Into Focus
Iran’s Revolutionary Guards reportedly fired missiles at commercial ships in the Strait of Hormuz, damaging two vessels without reported casualties. Oil has cooled from the panic phase, but this is a reminder that shipping risk can reprice quickly when the world’s key energy chokepoint is involved.

Saudi Arabia Cuts Prices, But Asia May Not Bite
Saudi Arabia’s latest oil price cut may still fail to pull in Asian buyers, with traders saying competing Gulf barrels remain cheaper. That points to a softer demand backdrop in Asia and keeps pressure on producers trying to defend market share without triggering a deeper price war.

Vertex Makes a $10 Billion Rare-Disease Bet
Vertex Pharmaceuticals agreed to buy Crinetics Pharmaceuticals for about $10 billion, adding rare endocrine disease treatments to its portfolio. The deal is a clear sign that large-cap biotech is still willing to pay up for approved assets and late-stage pipelines that can diversify revenue beyond core franchises.

Generic GLP-1 Competition Keeps Building
The FDA agreed to review Hybio’s generic versions of tirzepatide, adding another potential future challenger to Eli Lilly’s obesity and diabetes franchise. The patent wall still matters, but the market is already looking ahead to how pricing, access, and copycat competition could reshape the next phase of the GLP-1 trade.

Crinetics surged after Vertex agreed to acquire the company for $85 per share in cash, roughly a 100% premium to the prior close. Oppenheimer downgraded the stock to Perform after the deal, saying the shares are now trading on acquisition dynamics rather than fundamentals, with the transaction expected to close this quarter.

Fiserv moved higher after major banks, including JPMorgan, Bank of America, Wells Fargo, and PNC, reportedly held early talks to buy one of its debit-card networks. Fiserv owns the STAR and Accel networks, and bank ownership of payment rails could help large lenders reduce exposure to federal debit-card fee caps.

Rivian dropped after the EV maker announced a fully underwritten public offering of 75 million Class A shares priced at $20.14 each. The offering overshadowed stronger preliminary Q2 numbers, including projected revenue of $1.55 billion to $1.65 billion and cash, equivalents, and short-term investments of about $5.3 billion.

While many investors remain focused on AI and high-profile tech stocks, a different market trend is quietly gaining momentum.

One experienced researcher has released a free briefing explaining what's driving the shift and how investors may be able to position themselves as it unfolds.

See the Full Story

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.